Aytu Biopharma (AYTU) Non-Current Debt (2018 - 2026)

Aytu Biopharma (AYTU) has 9 years of Non-Current Debt data on file, last reported at $9.5 million in Q1 2026.

• On a quarterly basis, Non-Current Debt changed 0.15% year-over-year to $9.5 million in Q1 2026; TTM through Mar 2026 was $9.5 million, a 0.15% change from a year earlier, with the FY2025 full-year figure at $10.9 million, changed 0.17% from the prior year.
• Non-Current Debt for Q1 2026 stood at $9.5 million, down from $10.0 million in the prior quarter.
• Over the last five years, Non-Current Debt for AYTU reached as high as $15.0 million in Q3 2022 and fell as low as $9.5 million in Q1 2025.
• Historically, Non-Current Debt has averaged $12.2 million across 5 years, with a median of $11.1 million in 2023.
• Across the five-year window, Non-Current Debt jumped 11165.89% in 2022 and sank 33.35% in 2024, its largest moves.
• Year by year, Non-Current Debt stood at $14.5 million in 2022, then grew by 3.06% to $15.0 million in 2023, then sank by 33.35% to $10.0 million in 2024, then gained by 0.15% to $10.0 million in 2025, then decreased by 4.49% to $9.5 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $9.5 million in Q1 2026, $10.0 million in Q4 2025, and $10.4 million in Q3 2025.